Welcome to this module on retatrutide, one of the most talked-about advancements in metabolic and obesity medicine. If you've been hearing whispers about a "GLP-3" or a new super-drug in the pipeline, this is what they are referring to. Here is a complete breakdown of what retatrutide is, how it works, and what the latest clinical data says. What is Retatrutide? Retatrutide (LY3437943) is an investigational medication currently being developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and related metabolic conditions. Unlike first-generation medications that target a single receptor (like semaglutide) or second-generation dual-agonists (like tirzepatide), retatrutide is a first-in-class triple hormone receptor agonist. The Mechanism of Action: How It Works Retatrutide mimics three distinct naturally occurring hormones in the body simultaneously. This multi-target approach is why it is often unofficially referred to online as a "GLP-3." GLP-1 (Glucagon-Like Peptide-1): Curbs appetite, slows gastric emptying (keeping you fuller for longer), and improves post-meal blood sugar control. GIP (Glucose-Dependent Insulinotropic Polypeptide): Works alongside GLP-1 to regulate insulin secretion and further reduce appetite. Glucagon: This is the unique game-changer. Glucagon receptor agonism increases energy expenditure (calories burned) and promotes fat breakdown (lipolysis) in the liver. By combining all three, retatrutide not only suppresses caloric intake but also actively boosts metabolic output. The Latest Clinical Data (2025/2026 Updates) The numbers coming out of the latest Phase 3 clinical trials (specifically the TRIUMPH-4 trial released in late 2025/early 2026) are unprecedented in obesity pharmacotherapy: Massive Weight Reduction: Participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks. To put this in perspective, earlier generation drugs typically max out around 15–20% in similar timeframes.